Dark

Check out our API

MEIP
MEI Pharma, Inc.
stock NASDAQ

Inactive

Sep 10, 2025

3.07USD+10.432%(+0.29)4,033,050

Pre-market

0.00USD-100.000%(-2.78)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 3, 2022

04:01PM EST MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Dec 6, 2021

04:05PM EST MEI Pharma Announces Closing Of Public Offering Of Common Stock RTTNews

Dec 3, 2021

04:00PM EST MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Dec 1, 2021

08:52PM EST MEI Pharma Prices Public Offering Of 17.50 Mln Shares At $2.60/shr RTTNews

08:46PM EST MEI Pharma Announces Pricing of Public Offering of Common Stock Business Wire

08:41AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case Benzinga

08:36AM EST The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case Benzinga

Nov 30, 2021

05:03PM EST MEI Pharma Announces Proposed 17.5M Share Public Offering Of Common Stock Benzinga

05:00PM EST Mid-Afternoon Market Update: Dow Dips 500 Points; ImmunoGen Shares Spike Higher Benzinga

04:47PM EST The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout Benzinga

04:43PM EST MEI Pharma And Kyowa Kirin Announce Data From Ongoing Phase 2 TIDAL Study Evaluating Zandelisib; Zandelisib Demonstrated 70.3% Objective Response Rate; 35.2% Achieved Complete Response, 9.9% Of Patients Discontinued Due To Drug Related Adverse Event Benzinga

04:43PM EST MEI Pharma Shares Spike to Premarket High After Co and Kyowa Kirin Announced Data From Trial in Patients with Relapsed or Refractory Follicular Lymphoma Benzinga

04:00PM EST MEI Pharma Announces Proposed Public Offering of Common Stock Business Wire

07:00AM EST MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma Business Wire

Nov 29, 2021

04:00PM EST MEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma Business Wire

Nov 23, 2021

08:00AM EST MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors Business Wire

Nov 10, 2021

05:26PM EST MEI Pharma Q1 EPS $(0.13), Same YoY, Sales $13.39M Up From $3.83M YoY Benzinga

04:05PM EST MEI Pharma Reports First Quarter Fiscal Year 2022 Results and Operational Highlights Business Wire

08:13AM EST MEI Pharma And Kyowa Kirin Receive Orphan Drug Designation For Zandelisib For The Treatment Of Follicular Lymphoma Benzinga

08:13AM EST MEI Pharma And Kyowa Kirin Receive Orphan Drug Designation For Zandelisib For Treatment Of Follicular Lymphoma RTTNews

08:00AM EST MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma Business Wire

Nov 4, 2021

09:50AM EDT CORRECTION: MEI Pharma Ticker Is 'MEIP' Benzinga

09:50AM EDT MEI Pharma Announces Acceptance Of Three Abstracts For Presentation At 63rd Annual American Society Of Hematology Annual Meeting Dec. 11-14 Benzinga

09:00AM EDT MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting Business Wire

Nov 1, 2021

04:01PM EDT MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire

Sep 22, 2021

08:01AM EDT MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference PR Newswire

Sep 3, 2021

04:05PM EDT MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Sep 2, 2021

04:09PM EDT MEI Pharma FY21 EPS $(0.68), Down From $(0.51) YoY Benzinga

04:05PM EDT MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights PR Newswire

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

08:02AM EDT MEI Pharma to Present at Two Healthcare Conferences PR Newswire

04:09AM EDT Earnings Scheduled For September 2, 2021 Benzinga

Aug 26, 2021

08:01AM EDT MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide PR Newswire

Aug 17, 2021

08:08AM EDT MEI Pharma Says First Patient Dosed In Phase 3 COASTAL Study On Refractory Indolent Non Hodgkin's B-cell Lymphoma RTTNews

08:04AM EDT MEI Pharma, Kyowa Kirin Report First Patient Dosed In Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab In Relapsed, Refractory Indolent Non Hodgkin's B-Cell Lymphoma Benzinga

08:01AM EDT Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma PR Newswire

Aug 5, 2021

05:00PM EDT MEI Pharma Announces Brian Drazba, Chief Financial Officer of MEI Pharma, to Retire at the End of 2021 Benzinga

04:02PM EDT MEI Pharma Announces Planned Chief Financial Officer Transition PR Newswire

Aug 2, 2021

04:01PM EDT MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Jul 7, 2021

08:03AM EDT MEI Pharma Appoints Tina Beamon As Chief Compliance Officer RTTNews

08:01AM EDT MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer PR Newswire

Jul 1, 2021

04:01PM EDT MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Jun 9, 2021

06:06AM EDT MEI Pharma And Kyowa Kirin To Present Clinical Data From Ongoing Studies Evaluating Zandelisib For Lymphoma At 16th International Conference On Malignant Lymphoma Virtual Scientific Program Benzinga

06:03AM EDT MEI Pharma And Kyowa Kirin To Present Clinical Data From Studies Evaluating Zandelisib For Lymphoma At ICML RTTNews

06:01AM EDT Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program PR Newswire

Jun 7, 2021

08:14AM EDT MEI Pharma, Kyowa Kirin Announce First Patient With Marginal Zone Lymphoma Dosed In Expanded Global Phase 2 TIDAL Study RTTNews

08:03AM EDT MEI Pharma, Kyowa Kirin Report First Patient Dosed In Phase 2 Study For Marginal Zone Lymphoma Candidate Benzinga

08:01AM EDT MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma PR Newswire

Jun 4, 2021

08:01AM EDT MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO PR Newswire

May 19, 2021

05:25PM EDT Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021 Benzinga

05:00PM EDT MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American PR Newswire

May 12, 2021

10:04AM EDT MEI Pharma, Kyowa Kirin To Present Clinical Data From Phase 1b Study Of Zandelisib In Combination With Zanubrutinib At European Hematology Association 2021 Virtual Congress Benzinga

10:02AM EDT Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress PR Newswire

May 6, 2021

04:34PM EDT MEI Pharma Q3 EPS $(0.28) Down From $(0.11) YoY, Sales $2.42M Up From $1.24M YoY Benzinga

04:06PM EDT MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights PR Newswire

Apr 30, 2021

09:04AM EDT MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass; Names Richard Ghalie As New Chief Medical Officer Benzinga

09:02AM EDT MEI Pharma Announces Retirement Of Robert Mass Chief Medical Officer RTTNews

09:01AM EDT MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and PR Newswire

Apr 13, 2021

07:10AM EDT MEI Pharma,Kyowa Kirin Complete Enrollment In Follicular Lymphoma Primary Efficacy Population Of Phase 2 TIDAL Study RTTNews

07:08AM EDT MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from FDA Benzinga

07:01AM EDT Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDA) PR Newswire

Apr 12, 2021

10:11AM EDT MEI Pharma Saturday Morning Announced Preclinical Data Showing Ability Of Voruciclib to Regulate MYC, Synergize With KRAS Inhibitors At Ammerican Assocation For Cancer Research Meeting Apr. 13, 2021 Benzinga

Apr 10, 2021

08:31AM EDT MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to PR Newswire

Apr 8, 2021

09:36AM EDT MEI Pharma US Patent & Trademark Office Abstract For Co.'s 'COMBINATION THERAPIES' Benzinga

Apr 5, 2021

08:01AM EDT MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference PR Newswire

Mar 12, 2021

10:50PM EST MEI PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of MEI Pharma, Inc. - MEIP Business Wire

Mar 10, 2021

04:31PM EST MEI Pharma Highlights Will Present Study At American Association For Cancer Research Apr. 10, 2021 Benzinga

04:30PM EST (AACR) Annual Meeting 2021 Demonstrating that Voruciclib Inhibits KRAS Mutant Cancers in Pre-Clinical Models PR Newswire

Mar 2, 2021

08:02AM EST MEI Pharma to present at the virtual H.C. Wainwright Global Life Sciences PR Newswire

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 5, 2021

10:50PM EST Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. - MEIP PR Newswire

Feb 4, 2021

04:32PM EST MEI Pharma Q2 EPS $(0.16) Up From $(0.26) YoY, Sales $9.17M Up From $1.01M YoY Benzinga

04:05PM EST MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational PR Newswire

Jan 4, 2021

07:39AM EST MEI Pharma Reports Expansion Of Phase 1b Study Evaluating Zandelisib RTTNews

07:12AM EST MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update Benzinga

07:01AM EST MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and PR Newswire

Dec 18, 2020

10:50PM EST MEI PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. - MEIP Business Wire

Nov 10, 2020

05:20PM EST Mei Pharma Entered Into At-the-market Equity Offering Sales Agreement With Stifel, Nicolaus & Company & Credit Suisse Securities Benzinga

04:19PM EST MEI Pharma Q1 EPS $(0.02) Up From $(0.17) YoY Benzinga

04:06PM EST MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational PR Newswire

Nov 9, 2020

08:01AM EST MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences PR Newswire

Oct 23, 2020

04:51PM EDT Solutions Corporation, Honeywell International Inc., MEI Pharma, Inc., Nikola Corporation, The Chemours Company and YayYo, Inc. PR Newswire

Oct 9, 2020

06:20PM EDT SHAREHOLDER ALERT FILING DEADLINE: Pomerantz Law Firm Reminds GlobeNewswire Inc

11:56AM EDT MEIP FINAL DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Reminds MEI Pharma, PR Newswire

11:00AM EDT MEIP DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds MEI Pharma, Inc. Investors of Class Action and Lead Plaintiff Deadline: October 9, 2020 Business Wire

Oct 7, 2020

10:00AM EDT MEIP, COG & KODK Investor Update: Bronstein, Gewirtz & Grossman GlobeNewswire Inc

Oct 5, 2020

05:45PM EDT Portnoy Law: October 9th Deadline Alert in Lawsuit Filed On Behalf GlobeNewswire Inc

04:48PM EDT Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the Class Period), of the important October 9, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for MEI Pharma investors under the federal securities laws. GlobeNewswire Inc

Oct 2, 2020

10:00AM EDT MEIP, COG & KODK Investor Update: Bronstein, Gewirtz & Grossman GlobeNewswire Inc

07:10AM EDT Kyowa Kirin And MEI Pharma: First Patient Dosed In Japanese Pivotal Phase 2 Study Of Zandelisib RTTNews

07:05AM EDT MEI Pharma, Kyowa Kirin Report First Patient Dosed In Japanese Pivotal Phase 2 Study Of Zandelisib In Patients With Indolent B-Cell Non-Hodgkin's Lymphoma Benzinga

07:01AM EDT Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma PR Newswire

Sep 30, 2020

09:00PM EDT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That GlobeNewswire Inc

Sep 28, 2020

08:48PM EDT ROSEN, A LEADING LAW FIRM, Reminds MEI Pharma, Inc. Investors of Important PR Newswire

Sep 26, 2020

10:48PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Sep 24, 2020

03:18PM EDT Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the Class Period), of the important October 9, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for MEI Pharma investors under the federal securities laws. GlobeNewswire Inc

11:00AM EDT MEIP, COG & KODK Investor Update: Bronstein, Gewirtz & Grossman GlobeNewswire Inc

Sep 23, 2020

02:00PM EDT Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Sep 17, 2020

12:00PM EDT Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the Class Period), of the important October 9, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for MEI Pharma investors under the federal securities laws. GlobeNewswire Inc

Sep 16, 2020

08:56PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds GlobeNewswire Inc

02:00PM EDT Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Sep 15, 2020

08:02AM EDT MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing PR Newswire

Sep 14, 2020

09:22PM EDT Software Acquisition Group Inc. II Prices IPO Of 15 Mln Units At $10.00/unit RTTNews

09:18PM EDT Investment in MEI Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - MEIP PR Newswire

04:33PM EDT ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds MEI Pharma, Inc. Investors of PR Newswire

Sep 10, 2020

05:33PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds GlobeNewswire Inc

Sep 9, 2020

04:10PM EDT MEI Pharma FY20 EPS $(0.51) Down From $(0.24) YoY Benzinga

04:05PM EDT MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights PR Newswire

04:00PM EDT Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

04:01AM EDT Earnings Scheduled For September 9, 2020 Benzinga

Sep 8, 2020

06:45PM EDT Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the Class Period), of the important October 9, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for MEI Pharma investors under the federal securities laws. GlobeNewswire Inc

Sep 4, 2020

08:01AM EDT MEI Pharma to Present at Upcoming Investor Conferences in September PR Newswire

Sep 2, 2020

04:00PM EDT Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

08:01AM EDT MEI Pharma to Release 2020 Fiscal Year End Financial Results and Provide PR Newswire

Aug 31, 2020

04:00PM EDT Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the Class Period), of the important October 9, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for MEI Pharma investors under the federal securities laws. GlobeNewswire Inc

Aug 29, 2020

02:52PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds GlobeNewswire Inc

Aug 27, 2020

12:00PM EDT MEIP INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds GlobeNewswire Inc

Aug 26, 2020

06:00PM EDT Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Aug 25, 2020

09:00PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Aug 21, 2020

05:46PM EDT ROSEN, GLOBAL INVESTOR COUNSEL, Reminds MEI Pharma, Inc. Investors of the PR Newswire

Aug 20, 2020

05:35PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds GlobeNewswire Inc

Aug 19, 2020

07:00PM EDT Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Aug 18, 2020

07:30PM EDT Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for MEI Pharma investors under the federal securities laws. GlobeNewswire Inc

01:00PM EDT MEIP SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC GlobeNewswire Inc

Aug 16, 2020

12:43AM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds GlobeNewswire Inc

Aug 14, 2020

08:34PM EDT Lawsuit Against MEI Pharma, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - MEIP PR Newswire

Aug 13, 2020

05:43PM EDT Gainey McKenna & Egleston Announces A Class Action Lawsuit Has GlobeNewswire Inc

11:00AM EDT MEIP INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies MEI Pharma, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm Business Wire

08:30AM EDT Portnoy Law: Lawsuit Filed On Behalf of MEI Pharma, Inc. Investors GlobeNewswire Inc

Aug 12, 2020

11:00AM EDT Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm PR Newswire

Aug 10, 2020

06:35PM EDT Pomerantz Law Firm Announces the Filing of a Class Action against MEI Pharma, PR Newswire

Aug 4, 2020

08:01AM EDT MEI Pharma to Present at the BTIG Virtual Biotechnology Conference 2020 PR Newswire

Jul 21, 2020

08:54PM EDT Pomerantz LLP is investigating claims on behalf of investors of MEI Pharma, Inc. (MEI Pharma or the Company) (NASDAQ:MEIP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Share